SPECT/CT Imaging of Systemic AA-Amyloidosis in Mice

描述（由应用程序提供）：高分辨率成像正在成为 这是生物医学研究中非常宝贵的工具，就像它对临床医生一样。在 在临床上，成像提供了一种精确的，非侵入性的诊断手段， 影响治疗方法和预后。可惜 研究人员所需的高分辨率成像工具的开发已经滞后 在临床上，因此，体内代谢动力学的表征 病理学和随后开发的新的，有效的治疗方法， 受到阻碍。这在淀粉样蛋白相关领域尤其如此。 疾病，包括阿尔茨海默病，I1型糖尿病和原发性（AL） 淀粉样变性我们不可能完全领会和理解 这些疾病，以及他们可以停止的手段，没有 在个体动物体内进行纵向研究的能力。与 最后，发展高分辨率显微成像技术， 在体内检测和定量淀粉样蛋白沉积物是必要的和必要的。 我们打算通过设计和应用解决这些重要问题， 强大的新型双模态成像技术microSPECT，结合 microCT，由最先进的三维图像重建和分析支持 软件这项新技术将被用来鉴定放射性标记的淀粉样蛋白 在活体动物中沉积，并呈现淀粉样蛋白在 1内脏地形的高分辨率CT图像的背景。与此 技术，量化体内器官特异性淀粉样蛋白负荷的目标是 可实现的。 因此，目标是：㈠完成设计和执行 高分辨率，小动物专用双ISPECT/CT成像系统。 （ii）。建立了一个淀粉样蛋白定量系统， 与淀粉样蛋白负荷直接相关。(iii)使用这些技术来 在两种小鼠模型中研究系统性AA-淀粉样变性的进展， 其响应新型免疫疗法而消退。本研究不会 只会导致小动物成像领域的技术进步 和淀粉样蛋白特异性放射性示踪剂，但也将提供丰富的 体内淀粉样变性自然进展的信息，并建立一个 在人类疾病动物模型中筛选治疗药物的范例 疾病此外，淀粉样蛋白特异性成像技术的翻译 将产生切实的临床效益。

Description (provided by application): High resolution imaging is becoming an invaluable tool in biomedical research much as it has to the clinician. In the clinic, imaging offers a precise, non-invasive means of diagnosis and directly influences both the therapeutic approach and prognosis. Unfortunately, the development of high-resolution imaging tools demanded by researchers has lagged behind that of the clinic; thus, characterization of the kinetics of in vivo pathology and the subsequent development of novel, effective therapeutics has been hampered. This is particularly true in the field of amyloid- related diseases which include Alzheimer's disease, type I1 diabetes and primary (AL) amyloidosis. It is impossible to fully appreciate and understand the complexity of these diseases, and the means by which they may be halted, without the ability to perform longitudinal studies in individual animals in vivo. To that end, the development high- resolution micro-imaging technologies capable of detecting and quantifying amyloid deposits in vivo is warranted and imperative. We intend to address these important issues through the design and application of a powerful new dual-modality imaging technology, microSPECT, combined with microCT, supported by state-of-the-art 3-D image reconstruction and analysis software. This new technology will be employed to identify radiolabeled amyloid ldeposits in live animals and present the amyloid distribution within the context of a high-resolution CT image of the 1 visceral terrain. With this technology, the goal of quantifying organ-specific amyloid burden in vivo is attainable. The goals are thus to: (i) Complete the design and implementation of a high-resolution, small-animal speciJic dual lSPECT/CT imaging system. (ii). Develop a system of amyloid quantijkation in which microSPECT image data can be directly correlated to amyloid burden. (iii) Use these technologies to study the progression of systemic AA- amyloidosis in two murine models and the regression thereof in response to novel immunotherapies. This study will not only result in technological advancements in the field of small-animal imaging and amyloid-specific radio- tracers but will also provide a wealth of information on the natural progression of amyloidosis in vivo and establish a paradigm for the screening of therapeutic drugs in animal models of human disease. Furthermore, the translation of amyloid-specific imaging technologies will yield tangible clinical benefit.